Back to search

Article

A novel type of monocytic leukemia stem cell revealed by the clinical use of venetoclax-based therapy

2022-12-04

Abstract excerpt

The BCL-2 inhibitor venetoclax has recently emerged as an important component of acute myeloid leukemia (AML) therapy. Notably, use of this agent has revealed a previously unrecognized form of pathogenesis characterized by monocytic disease progression. We demonstrate that this form of disease arises from a fundamentally different type of leukemia stem cell (LSC), which we designate as monocytic LSC (m-LSC), that...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
69f8d59f-93ac-5288-b862-90b43e81d93f
DOI
10.1101/2022.12.04.519036
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
A novel type of monocytic leukemia stem cell revealed by the clinical use of venetoclax-based therapyDOI 10.1101/2022.12.04.519036
A Novel Type of Monocytic Leukemia Stem Cell Revealed by the Clinical Use of Venetoclax-Based TherapySemantic proximity
Monocytic Subclones Confer Resistance to Venetoclax-Based Therapy in Patients with Acute Myeloid LeukemiaSemantic proximity
PU.1 inhibition sensitizes stem-monocytic AML to BCL2 blockadeSemantic proximity
Targeting Acute Myeloid Leukemia with Venetoclax; Biomarkers for Sensitivity and Rationale for Venetoclax-Based Combination TherapiesSemantic proximity
Transcriptional and phenotypic heterogeneity underpinning venetoclax resistance in AMLSemantic proximity
Hematopoietic Stem Cells Undergo Differentiation State Reprogramming to Overcome Venetoclax Sensitivity in Patients with Myelodysplastic SyndromesSemantic proximity
Clinical Correlates of Venetoclax-Based Combination Sensitivities to Augment Acute Myeloid Leukemia TherapySemantic proximity
Genetic and Phenotypic Correlates of Clinical Outcomes with Venetoclax in Acute Myeloid Leukemia: The GEN-PHEN-VEN Study.Semantic proximity
Venetoclax in Acute Myeloid Leukemia: Molecular Basis, Evidences for Preclinical and Clinical Efficacy and Strategies to Target ResistanceSemantic proximity
Erythroid-predominant myelodysplastic neoplasms exhibit a distinct genomic landscape with poor outcomes after venetoclax-based therapy.Semantic proximity
Erythroid/megakaryocytic differentiation confers BCL-XL dependency and venetoclax resistance in acute myeloid leukemiaSemantic proximity
Combinatorial BCL2 Family Expression in Acute Myeloid Leukemia Stem Cells Predicts Clinical Response to Azacitidine/VenetoclaxSemantic proximity
Select a neighboring publication to make it the new centre.